Novartis to Acquire Avidity Biosciences in $12bn Deal
Swiss pharmaceutical giant Novartis has agreed to acquire U.S.-based Avidity Biosciences in a $12 billion all-cash deal, strengthening its late-stage neuroscience pipeline and expanding its presence in RNA-based therapeutics. Strategic Expansion into RNA Therapeutics On 26 October 2025, Novartis AG announced it had entered into a definitive agreement to acquire Avidity Biosciences, a California-based biotech […]
Continue Reading